文献速递白血病

急性髓系白血病强化化疗的生存预测

Prediction of survival with intensive chemotherapy in acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2022-04-16

该研究分析了1980年至2021年接受强化化疗的3728例新诊断急性髓系白血病(AML)患者的生存,按3:1分为训练组(n=2790)和验证组(n=938)。多因素分析识别出12个与较差生存独立相关的 adverse 预后变量,并据此将患者分为预后良好(7%)、中等(43%)、不良(39%)和极差(11%)四组,5年生存率分别为69%、36%、13%和3%(p < .001)。该预测模型在独立队列中得到验证,并发现NPM1(有利)、PTPN11和TP53(均不利)突变具有分子预后价值。

要点

  • 12个不良预后变量包括年龄较大、治疗相关髓系肿瘤、体能状态差、心脏合并症、白细胞增多、贫血、血小板减少、肌酐和乳酸脱氢酶升高、细胞遗传学异常及诊断时感染(不明原因发热除外)。
  • 四组预后良好、中等、不良、极差分别占7%、43%、39%、11%,5年生存率分别为69%、36%、13%、3%(p < .001)。
  • 在分子突变亚组中,NPM1突变为有利预后因素,PTPN11和TP53突变为不利预后因素。

核心结论

  • 新提出的AML强化化疗生存预测模型稳健,可用于告知患者预后、调整缓解期治疗(如提议首次缓解期行异基因干细胞移植)以及比较未来研究性治疗的结果和获益。

研究设计与样本

  • 研究分析了1980年至2021年接受强化化疗的3728例新诊断AML患者,按3:1分为训练组(n=2790)和验证组(n=938),评估27个特征与生存的关联。

主要发现

  • 训练队列多因素分析识别出12个与较差生存独立相关的 adverse 预后变量:年龄较大、治疗相关髓系肿瘤、体能状态差、心脏合并症、白细胞增多、贫血、血小板减少、肌酐和乳酸脱氢酶升高、细胞遗传学异常及诊断时感染(不明原因发热除外)。
  • 患者分为预后良好(7%)、中等(43%)、不良(39%)和极差(11%)四组,估计5年生存率分别为69%、36%、13%和3%(p < .001)。
  • 在具有分子突变谱的患者亚组中,校正先前因素效应后,NPM1(有利)、PTPN11和TP53(均不利)突变被识别为分子预后因素。

关键数值与推荐

  • 预后良好组占7%,5年生存率69%;中等组占43%,5年生存率36%;不良组占39%,5年生存率13%;极差组占11%,5年生存率3%(p < .001)。

临床怎么用

  • 作者认为该预测模型可用于告知患者预后、调整缓解期治疗(如提议首次缓解期行异基因干细胞移植)以及比较未来研究性治疗的结果和获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progress with intensive chemotherapy and supportive care measures has improved survival in newly diagnosed acute myeloid leukemia (AML). Predicting outcome helps in treatment decision making. We analyzed survival as the treatment endpoint in 3728 patients with newly diagnosed AML treated with intensive chemotherapy from 1980 to 2021. We divided the total study group (3:1 basis) into a training (n = 2790) and a validation group (n = 938). The associations between survival and 27 characteristics were investigated. In the training cohort, the multivariate analysis identified 12 consistent adverse prognostic variables independently associated with worse survival: older age, therapy-related myeloid neoplasm, worse performance status, cardiac comorbidity, leukocytosis, anemia, thrombocytopenia, elevated creatinine and lactate dehydrogenase, cytogenetic abnormalities, and the presence of infection at diagnosis except fever of unknown origin. We categorized patients into four prognostic groups, favorable (7%), intermediate (43%), poor (39%), and very poor (11%) with estimated 5-year survival rates of 69%, 36%, 13%, and 3% respectively (p < .001). The predictive model was validated in an independent cohort. In a subset of patients with molecular mutation profiles, adding the mutation profiles after accounting for the effects of previous factors identified NPM1 (favorable), PTPN11, and TP53 (both unfavorable) mutations as molecular prognostic factors. The new proposed predictive model for survival with intensive chemotherapy in patients with AML is robust and can be used to advise patients regarding their prognosis, to modify therapy in remission (e.g., proposing allogeneic stem cell transplantation in first remission), and to compare outcome and benefits on future investigational therapies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Sasaki K, Ravandi F, Kadia T, et al. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022. PMID: 35384048. doi:10.1002/ajh.26557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。